GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise
GN Hearing, the global leader in hearing aid innovation, today announces the expansion of the popular ReSound OMNIA family, providing more options to address the biggest unmet need for people with hearing loss: hearing speech in noisy environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005021/en/
GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise (Photo: Business Wire)
Despite hearing in noise being the main reason why people get hearing aids, 86% of people who wear them still struggle with speech understanding in noise.1 The launch will see GN Hearing expand the premium natural sound offering of ReSound OMNIA into more devices to match the needs and wants of a larger group of people. ReSound OMNIA provides an exceptional 150% improvement in speech understanding in noise2 and is the only hearing solution to simultaneously combine two benefits – narrow beamforming directionality for hearing in noise and omnidirectional listening for a natural listening experience without feeling cut off.2
The ReSound OMNIA technology is available in a full line-up of popular styles to cater to all hearing needs and preferences. In addition to the Receiver-in-Ear hardware launched in August 2022, the family now includes miniRIE, Behind-the-Ear (BTE) and custom-made styles to ensure even more people living with hearing loss will be able to access GN’s most advanced technology, and with greater listening comfort.
As part of the expansion, GN is launching their smallest rechargeable RIE yet, the miniRIE, for a stylish and cosmetic fit without compromising on sound quality. The miniRIE is designed for best wearing comfort, thanks to its size, shape and the soft curves. The device offers all day battery life for worry-free use throughout the day and without the hassle of exchanging fiddly batteries on the go.
GN Hearing CEO and President, Gitte Aabo explains, “Nobody should feel limited by noisy environments. I’m delighted that more people can now benefit from these new best-in-class hearing aids which will help improve hearing in noise without leaving anyone feeling cut off. People with hearing challenges can now strengthen their connections to people and the world around them and hear the sounds that matter.”
All solutions under the ReSound OMNIA family will provide enhanced connectivity, whether users are streaming phone calls or music to their ears. Users can answer calls with just a tap on their hearing aid and enjoy crystal-clear conversations with outstanding sound quality – all without having to take their smart phone out of their pocket.*
The extended ReSound OMNIA portfolio is planned for Regulatory clearance and will be available globally starting with the US and Canada on February 23, 2023, along with the equivalent Beltone Achieve line-up.
For more information, visit the ReSound website.
1 MarkeTrak 22, 2022
2 Jespersen et al (2022)
* ReSound OMNIA hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation) or later, with software updates iOS 15.3 and iPadOS 15.3 or later.
- ENDS -
NOTES TO EDITORS
About GN Group
GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook .
© 2023 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005021/en/
Contact information
For further information, please contact:
Press and the media
Aysel Cengiz
Director, Global PR & Communications
Tel: +45 2894 1821
Steen Frentz Laursen
Vice President, Corporate Communications
Tel: +45 45 75 07 21
Investors and analysts
Anne Sofie Staunsbæk Veyhe
Vice President, IR, Treasury and M&A
Tel: +45 45 75 85 06
Rune Sandager
Senior Director, Investor Relations
Tel: +45 45 75 92 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 16:10:00 EEST | Press release
Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025 Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value. Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never c
KBS Partners with Rimini Street to Accelerate its AI Vision17.9.2025 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Korean Broadcasting System (KBS) has partnered with Rimini Street to provide support for its SAP ECC 6.0, a strategic move that has helped to fund and accelerate its AI vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917964406/en/ KBS Partners with Rimini Street to Accelerate its AI Vision Central to KBS’s AI-enabled future is the valuable data stored in its core SAP system, a source that encompasses more than 20 years of information unique to the organization. Drawing upon this rich resource, KBS plans to create multiple AI projects and ongoing programs to maximize talent capabilities, improve time to market for new programs and increase operational efficiencies throughout the organizat
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom